Omacetaxine (HHT*) CML Trials

OR

Have you or someone you know been diagnosed with Chronic Myelogenous Leukemia (CML) and failed treatment with Gleevec^® (imatinib mesylate), Sprycel^® (dasatinib) or Tasigna^® (nilotinib)?

Have you or someone you know been identified with the T315I mutation?

This website will allow you to find out more information about clinical trials that are being conducted by ChemGenex Pharmaceuticals and The Stragen Group for these CML patients.

For Physicians | For Patients and Caregivers
About Us | Contact Us | Terms and Conditions | Privacy Policy

*Omacetaxine mepesuccinate is the United States Adopted Names (USAN)
approved International Non-Proprietary Name (INN) for homoharringtonine or HHT.
Gleevec^® is a registered trademark of Novartis AG.
Sprycel^® is a registered trademark of Bristol-Myers Squibb Company.
Tasigna^® is a registered trademark of Novartis AG.